The need to change our objective for artificial heart development: from totally implantable permanent ventricular assist devices to wearable therapeutic ventricular assist devices.
As a therapeutic VAD to be combined with drugs, apheresis, and cellular implants, it is advisable to develop a wearable VAD for less than 6 months of application. Such an example was shown by describing the therapeutic BCM Gyro centrifugal VAD.